Form 4: Avidity Biosciences' Chief Program Officer Exercises Options and Sells Shares

Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 3, 2025, Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, exercised stock options to acquire 5,875 shares of common stock at a price of $14.70 per share.
• Simultaneously, Gallagher sold 5,875 shares of common stock at a weighted-average price of $29.414, with individual sales ranging from $28.88 to $30.05.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2024.
• Following these transactions, Gallagher directly owns 50,554 shares of Avidity Biosciences common stock and holds options for 19,375 shares.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine disclosure of insider trading activity under a pre-arranged plan. It doesn't necessarily indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company executives. It's common for executives to utilize Rule 10b5-1 plans to manage their stock holdings and avoid accusations of trading on inside information.

Stakeholder Impact

• Shareholders are informed about insider transactions, promoting transparency.
• The transactions may have a minor impact on the stock price due to the volume of shares traded.

Key Dates